Abbott Reports Strong Third-Quarter Growth and Adjusts Guidance for 2025
Abbott Reports Strong Third-Quarter Growth and Adjusts Guidance for 2025
On October 15, 2025, Abbott Laboratories (NYSE: ABT) shared its financial performance for the third quarter, revealing impressive growth metrics that highlight the company's resilience and market strength. This quarter's reported sales saw a growth of 6.9%, significantly driven by solid demand across various sectors.
Key Financial Highlights
- - Reported Sales Growth: The company recorded a 6.9% increase, with organic sales growth at 5.5%. Notably, when excluding COVID-19 testing-related sales, the growth was observed at 7.5%.
- - Earnings Per Share: Abbott posted a GAAP diluted earnings per share (EPS) of $0.94, while the adjusted EPS moved up to $1.30, excluding specific items. This reflects a strategic focus on maintaining profitable ventures and capitalizing on enhanced operational efficiencies.
- - Operating Margin: An operating margin of 18.1% of sales was reported, with an adjusted margin reaching 23.0%, indicating a 40 basis point increase from the prior period.
Year-to-Date Performance
For the first nine months of 2025, Abbott's reported sales grew by 6.1%. Organic sales, which exclude COVID-19 tests, enjoyed a healthy 6.4% increase. The leadership reiterated its commitment to organic sales growth guidance for the full year, which is positioned between 7.5% to 8.0% when excluding COVID-19 testing, illustrating a firm belief in the company’s core capabilities and product offerings.
Breakout by Segment
Abbott's performance excellence can be attributed to strong results across multiple segments:
- - Nutrition: Sales within this category rose by 4.2%. Adult nutrition products, especially essential brands like Ensure® and Glucerna®, performed excellently, boosting sales by 5.8%.
- - Diagnostics: This segment faced challenges, exhibiting a decline of 6.6% in sales, impacted primarily by reduced demand for COVID-19 tests, which accounted for $69 million this quarter compared to $265 million in Q3 2024.
- - Medical Devices: The standout segment, medical devices sales surged by 14.8%, led by double-digit growth in diabetes care and cardiovascular products. The impressive performance was underlined by continuous glucose monitor sales reaching $2.0 billion and achieving growth of 20.5%.
Product Innovations and Approvals
Abbott's commitment to innovation and patient care is exemplified by significant advancements, including:
- - TriClip® Approval in Japan: Abbott received regulatory approval for TriClip, which serves as a minimally invasive treatment option for patients with tricuspid regurgitation—a major step in addressing heart valve disorders.
- - Navitor® System: The recent CE Mark approval for the Navitor transcatheter aortic valve implantation system demonstrates Abbott's ongoing dedication to improving cardiac care for at-risk populations.
- - New Treatment Guidelines: The European Society of Cardiology (ESC) Congress released new treatment guidelines supporting the use of MitraClip® and TriClip, providing steadfast validation of Abbott's contributions to medical practices around valvular heart disease.
Leadership Insights
Robert B. Ford, chairman and CEO, remarked on the robust performance saying, “Our third-quarter results demonstrate our ability to deliver consistent, high-quality performance. Our differentiated product pipeline continues to power our performance and positions Abbott to deliver durable long-term value to our shareholders.”
Conclusion
Abbott's strong quarterly results depict an organization firmly on a growth trajectory backed by innovative products and established market presence. As Abbott navigates the complexities of healthcare demand and supply post-pandemic, its strategic decisions and product innovations ensure not only resilience but also a promising future for stakeholders. The company remains committed to providing shareholder value and advancing healthcare solutions worldwide.
For continued updates about Abbott’s financial performance, tune into their earnings conference call at the Investor Relations website. With a steadfast focus on innovation and market responsiveness, Abbott stands poised to meet future challenges and opportunities head-on.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.